---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-23-000039"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T05:36:37.413932+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health Q1 revenue up 26% to $2.3M; OvaSuite volume +29%

## Summary
- Product revenue $2.3M (+26% YoY); OvaSuite volume 6,259 units (+29% YoY).
- Cash used in operations $5.7M, down 44% from $10.2M YoY; total cash $7.5M at Mar 31.
- Gross margin 51.4% vs 50.8%; revenue per test $370 (-2%).
- 2H 2023 milestones: OvaWatch serial monitoring test study completion, EndoCheck launch.
- Board approved 1-for-15 reverse stock split; secured up to $22.5M in capital facilities.

## SEC filing metadata
- accession: 0000926617-23-000039
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661723000039/0000926617-23-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661723000039/awh-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-23-000039
- JSON: https://secwatch.observer/filing/0000926617-23-000039.json
- Plain text: https://secwatch.observer/filing/0000926617-23-000039.txt

## Key facts
- Earnings Releases
  Aspira Women's Health Inc. reported the three months ended March 31, 2023 results: revenue $2.3 million. Guidance reaffirmed.
  - Period: the three months ended March 31, 2023
  - Revenue: $2.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: regardless of any incorporation by reference language in such filing.  --- EX-99.1 (EX-99.1) --- 2023-05-11 8K Ex 991 Exhibit 99 .1 First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year  First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year  First Quarter cash used in operations of $5.7 million, a
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000039/0000926617-23-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.